Interleukin-5 Receptor alpha-directed Cytolytic Antibody class drugs
1 result
Fasenra (benralizumab)
(Benralizumab)AstraZeneca Pharmaceuticals LP
Usage: FASENRA is indicated for add-on maintenance treatment of severe asthma in patients aged 6 and older with an eosinophilic phenotype, and for adults with eosinophilic granulomatosis with polyangiitis (EGPA). It is not for acute bronchospasm relief.